Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 315
- 试验地点
- 9
- 主要终点
- Complete Pathologic Response (pCR)
研究概览
简要总结
The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response.
Each participant will be treated with 8 weeks of a luteinizing hormone-releasing hormone agonist (LHRHa) plus apalutamide (APA) while genome sequence characterization is being done. Participants with biopsy specimens deemed unevaluable for genomic testing will remain on LHRHa plus APA for an additional 16 weeks.
Participants with evaluable tissue will be assigned to one of the open-label sub-studies on the basis of genomic profiling results. Within each group, they will be randomized to a specific treatment arm either LHRHa plus APA alone or adding abiraterone acetate and prednisone, docetaxel or niraparib.
The study will evaluate the response rate and outcomes after radical prostatectomy in each arm of the trial.
详细描述
This is a multi-centre adaptive multi-arm phase II study. Participants are treated with an induction period of at least 8 weeks of LHRH agonist/antagonist (LHRHa) plus apalutamide (APA) while genome sequence characterization is being done.
Genomic sequencing analysis will be performed centrally by Tempus, a CLIA (Clinical Laboratory Improvement Amendments)-certified laboratory. For the DNA gene profiling, formalin-fixed paraffin-embedded (FFPE) prostate cancer and surrounding healthy tissue from diagnostic biopsies will be used for genetic analysis. Copy number profiling will be performed using array Comparative Genomic Hybridisation (aCGH). Targeted sequencing using MiSeq (Illumina) and Ion Proton (Life Technologies) platforms will be performed to identify mutations in a panel of 648 genes.
Based on previous studies, we conservatively expect up to 25% of unevaluable needle biopsy specimens with inadequate/insufficient tumor tissue for genome sequencing. The patients with unevaluable tissue will continue on the master protocol (LHRHa + APA) for an additional 16 weeks followed by radical prostatectomy.
The genomically evaluable patients will be assigned to a specific sub-protocol according to the results of the genomic profile and randomized to a treatment arm within the sub-protocol for 16 weeks, with additional inclusion and exclusion criteria specified in dedicated sub-protocols. Radical prostatectomy will follow sub-protocol treatment.
Sub-protocol 1 - AR axis: No targetable actionable aberration; presence of TMPRSS2-ERG fusion, CHD1 loss or SPOP mutations: (~50% expected prevalence in study population) randomized to:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •i. Males ≥ 18 years of age. ii. Histologically confirmed adenocarcinoma of the prostate without pathologic evidence of small cell differentiation at the time of initial diagnosis. Screening biopsy must be performed within 4 months of the screening visit.
- •iii. High-risk localized prostate cancer as defined by at least one of the following:
- •Any combination of Gleason Score 4+3=7 and Gleason Score 8 (4+4 or 5+3) in ≥6 systematic cores (with ≥1 core Gleason Score 8 [4+4 or 5+3] included);
- •Any combination of Gleason Score 4+3 and Gleason Score 8 (4+4 or 5+3) in ≥3 systematic cores and PSA ≥20 ng/mL (with at least 1 core Gleason Score 8 [4+4 or 5+3] included);
- •Gleason Score ≥9 in at least 1 systematic or targeted core;
- •At least 2 systematic or targeted cores with Gleason Score ≥8, each with at least 80% involvement"; or
- •Gleason Score 4+3=7 in at least 6 systematic or targeted cores and PSA ≥20 ng/mL iv. Participants must provide consent blood collection and evaluation of diagnostic prostate tissue for genetic testing at registration and prior to assignment by a central reference laboratory.
- •v. No prior systemic or localized treatment for prostate cancer (exception: up to 12 weeks of luteinizing hormone-releasing hormone agonist or antagonist (LHRHa) and bicalutamide is allowable prior to registration).
- •vi. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Appendix II) and a life expectancy of ≥ 3 years in the opinion of the treating oncologist.
- •vii. Laboratory Requirements: Participants must have adequate end-organ function and all laboratory tests must be performed within 8 weeks prior to registration into master protocol (Table 1).
- •viii. Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to registration in the trial to document their willingness to participate.
- •ix. Archival tissue must be available for genetic analysis.
排除标准
- •Participants will be excluded if ANY of the following criteria are met:
- •i. Received more than 12 weeks of LHRHa prior to registration. ii. Stage T4 prostate cancer by clinical examination or radiologic evaluation. iii. Hypogonadism or severe androgen deficiency as determined by the treating physician, or screening serum testosterone less than 50 ng/dL (1.7 nmol/L) iv. Participants with serious illnesses or medical conditions which could cause unacceptable safety risks or would not permit the participant to be managed according to the protocol. This includes but is not limited to:
- •Active infection or chronic liver disease requiring systemic therapy;
- •Active or known human immunodeficiency virus (HIV) with detectable viral load;
- •Participants with uncontrolled hypertension or diabetes.
- •Uncontrolled or recent clinically significant cardiac disease, including history of any of the following within 12 months prior to screening:
- •Severe or unstable angina, symptomatic pericarditis, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), clinically significant ventricular arrhythmias or New York Heart Association Class II to IV heart disease, coronary artery bypass grafting, coronary angioplasty, stenting, or myocardial infarction; uncomplicated deep vein thrombosis is not considered exclusionary).
- •History of any cardiac arrhythmias that preclude prostatectomy or treatment with study drugs, e.g. ventricular, supraventricular, nodal arrhythmias, or conduction abnormality.
- •v. Participants who are unable to swallow oral medication and/or have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
- •vi. Participants with a history of hypersensitivity to any of the study drugs or any excipient.
- •vii. Participants with a history of non-compliance to medical regimens. viii. Severe concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the participant inappropriate for registration or prostatectomy.
- •ix. Prior androgen deprivation, chemotherapy, surgery, or radiation for prostate cancer.
- •x. Receiving concurrent androgens, estrogens, or progestational agents, or received any of these agents within the 6 months prior to registration.
- •xi. M1 by conventional imaging (CT, bone scan) or PSMA-PET. Participants with oligometastatic (<3) metastases by PSMA imaging only who are deemed candidates for radical prostatectomy are eligible.
研究组 & 干预措施
Group 1a
LHRHa plus apalutamide.
干预措施: Apalutamide 60mg Tab (Drug)
Group 4
LHRHa plus apalutamide plus atezolizumab
干预措施: Apalutamide 60mg Tab (Drug)
Group 1b
LHRHa plus apalutamide plus abiraterone acetate plus prednisone.
干预措施: Prednisone 5mg Tab (Drug)
Group 2a
LHRHa plus abiraterone acetate plus prednisone.
干预措施: Abiraterone Acetate 250mg (Drug)
Group 2a
LHRHa plus abiraterone acetate plus prednisone.
干预措施: Prednisone 5mg Tab (Drug)
Group 2b
LHRHa plus abiraterone acetate plus prednisone plus docetaxel.
干预措施: Abiraterone Acetate 250mg (Drug)
Group 2b
LHRHa plus abiraterone acetate plus prednisone plus docetaxel.
干预措施: Prednisone 5mg Tab (Drug)
Group 3
LHRHa plus abiraterone acetate plus prednisone plus niraparib
干预措施: Abiraterone Acetate 250mg (Drug)
Group 3
LHRHa plus abiraterone acetate plus prednisone plus niraparib
干预措施: Prednisone 5mg Tab (Drug)
Group 3
LHRHa plus abiraterone acetate plus prednisone plus niraparib
干预措施: Niraparib 100mg Oral Capsule (Drug)
Group 5
LHRHa plus abiraterone acetate plus prednisone plus tazemetostat
干预措施: Abiraterone Acetate 250mg (Drug)
Group 5
LHRHa plus abiraterone acetate plus prednisone plus tazemetostat
干预措施: Prednisone 5mg Tab (Drug)
Group 5
LHRHa plus abiraterone acetate plus prednisone plus tazemetostat
干预措施: Tazemetostat Pill (Drug)
Group 6
LHRHa plus abiraterone acetate plus prednisone plus Capivasertib
干预措施: Capivasertib (Drug)
Group 1b
LHRHa plus apalutamide plus abiraterone acetate plus prednisone.
干预措施: Abiraterone Acetate 250mg (Drug)
Group 1b
LHRHa plus apalutamide plus abiraterone acetate plus prednisone.
干预措施: Apalutamide 60mg Tab (Drug)
Group 6
LHRHa plus abiraterone acetate plus prednisone plus Capivasertib
干预措施: Abiraterone Acetate 250mg (Drug)
Group 6
LHRHa plus abiraterone acetate plus prednisone plus Capivasertib
干预措施: Prednisone 5mg Tab (Drug)
Group 2b
LHRHa plus abiraterone acetate plus prednisone plus docetaxel.
干预措施: Docetaxel (Drug)
Group 4
LHRHa plus apalutamide plus atezolizumab
干预措施: Atezolizumab (Drug)
结局指标
主要结局
Complete Pathologic Response (pCR)
时间窗: 6 years
Pathological Minimal Residual Disease (pMRD): pathological minimal residual disease (pMRD) is defined as residual tumour 5mm or less.
Pathological Minimal Residual Disease (pMRD)
时间窗: 6 years
Pathological minimal residual disease is defined as residual tumour 5 mm or less.
次要结局
- Pain level assessment(6 years)
- Generic Quality of Life (QoL)(6 years)
- Quality of Life-Prostate Cancer Patients(6 years)
研究者
Martin Gleave
Principal Investigator/Study Chair
University of British Columbia